| Sloan's Lake Rehabilitation Center | |
| 1601 Lowell Blvd, Denver, Colorado 80204 | |
| (303) 534-2211 | |
| Name | Sloan's Lake Rehabilitation Center |
|---|---|
| Location | 1601 Lowell Blvd, Denver, Colorado |
| Certified By | Medicare |
| No. of Certified Beds | 42 |
| Occupancy Rate | 98.57% |
| Medicare ID (CCN) | 065404 |
| Legal Business Name | Lakewood Healthcare, Inc. |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1437300746 |
| Organization Name | POINT PLEASANT DENVER LLC |
| Address | 1601 Lowell Blvd, 5th Floor, Denver, CO 80204 |
| Phone Number | 610-896-4410 |
News Archive
The country's top doctors and medical experts are urging pregnant women to get their COVID-19 vaccine as soon as possible, as new data published by the UK Health Security Agency (UKHSA) today [November Thursday 25] provides further evidence that the vaccines are safe for this group.
Insurance companies should disclose more information about how they spend money to justify their rate hikes, Health and Human Services Secretary Kathleen Sebelius told a group of insurance executives during a White House meeting Thursday, the San Francisco Chronicle reports.
The University of Louisville announced today that it will receive a tuberculosis (TB) biomarkers grant through the Bill & Melinda Gates Foundation's Grand Challenges in Global Health program, an initiative which seeks to overcome persistent bottlenecks in creating new tools that can radically improve health in the developing world. James E. Graham, Ph.D., associate professor of microbiology and immunology at the UofL School of Medicine, will pursue an innovative research project to identify and validate TB biomarkers, titled "Disposable Sampling Plate and Breath Test to Identify Patients with Active Tuberculosis."
Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a single intradermal (ID) electroporation boost of its SynCon avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines.
Biogen Idec and Biovitrum AB (STO: BVT) today announced that they plan to advance the companies' long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial in hemophilia B patients.
› Verified 8 days ago
| NPI Number | 1871846493 |
| Organization Name | LAKEWOOD HEALTHCARE, INC. |
| Doing Business As | SLOAN'S LAKE REHABILITATION CENTER |
| Address | 1601 North Lowell Boulevard, Denver, CO 80204 |
| Phone Number | 303-534-2211 |
News Archive
The country's top doctors and medical experts are urging pregnant women to get their COVID-19 vaccine as soon as possible, as new data published by the UK Health Security Agency (UKHSA) today [November Thursday 25] provides further evidence that the vaccines are safe for this group.
Insurance companies should disclose more information about how they spend money to justify their rate hikes, Health and Human Services Secretary Kathleen Sebelius told a group of insurance executives during a White House meeting Thursday, the San Francisco Chronicle reports.
The University of Louisville announced today that it will receive a tuberculosis (TB) biomarkers grant through the Bill & Melinda Gates Foundation's Grand Challenges in Global Health program, an initiative which seeks to overcome persistent bottlenecks in creating new tools that can radically improve health in the developing world. James E. Graham, Ph.D., associate professor of microbiology and immunology at the UofL School of Medicine, will pursue an innovative research project to identify and validate TB biomarkers, titled "Disposable Sampling Plate and Breath Test to Identify Patients with Active Tuberculosis."
Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a single intradermal (ID) electroporation boost of its SynCon avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines.
Biogen Idec and Biovitrum AB (STO: BVT) today announced that they plan to advance the companies' long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial in hemophilia B patients.
› Verified 8 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
The country's top doctors and medical experts are urging pregnant women to get their COVID-19 vaccine as soon as possible, as new data published by the UK Health Security Agency (UKHSA) today [November Thursday 25] provides further evidence that the vaccines are safe for this group.
Insurance companies should disclose more information about how they spend money to justify their rate hikes, Health and Human Services Secretary Kathleen Sebelius told a group of insurance executives during a White House meeting Thursday, the San Francisco Chronicle reports.
The University of Louisville announced today that it will receive a tuberculosis (TB) biomarkers grant through the Bill & Melinda Gates Foundation's Grand Challenges in Global Health program, an initiative which seeks to overcome persistent bottlenecks in creating new tools that can radically improve health in the developing world. James E. Graham, Ph.D., associate professor of microbiology and immunology at the UofL School of Medicine, will pursue an innovative research project to identify and validate TB biomarkers, titled "Disposable Sampling Plate and Breath Test to Identify Patients with Active Tuberculosis."
Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a single intradermal (ID) electroporation boost of its SynCon avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines.
Biogen Idec and Biovitrum AB (STO: BVT) today announced that they plan to advance the companies' long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial in hemophilia B patients.
› Verified 8 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $5415 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|